Liquid Biopsy Blood Test For Cancer Recurrence Detection And Monitoring Launched By MedGenome

Bangalore based MedGenome, genomics based research and diagnostics company, announced the launch of “ONCOTRACK” a liquid biopsy based non-invasive screening test that is set to transform the way physicians in India identify genetic alterations, interpret, assess and treat various forms of cancer.

“Management of cancer will undergo a massive transformation in India with NGS based liquid biopsies. We are constantly striving to get the most advanced genetic testing technology/technique at affordable prices to the patients and Oncotrack is one such offering.”, said Sam Santhosh, Chairman, MedGenome.

India is likely to have over 1.73 Million new cases of cancer and over 880,000 deaths due to the disease by 2020. Around 70% of all cancer patients approach the doctor when the disease has advanced, and the chances of cure are very low.

The test developed entirely by MedGenome, is the only one to be validated in India and verified from samples of cancer patients from across the country. The test screens the samples by analyzing cell-free DNA that is isolated from the patients’ blood.  Using high end sequencing technology, the screening process identifies specific gene mutations that are linked with Melanoma, Lung and Colon cancers. The test facilitates detection of mutation …

To read more subscribe
Show More

Related Articles

Leave a Reply